|
Patent landscape, scope, and claims: |
Executive summary
- US Patent 5,177,080 is a chemical and use patent focused on substituted pyridyl dihydroxy heptenoic acids (including specific stereoisomer/enantiomer claims) and pharmaceutically acceptable salts, plus a composition and method of use for inhibiting HMG-CoA (3-hydroxy-3-methyl-glutaryl coenzyme A).
- From the claim set provided, the enforceable scope is anchored on:
- a defined core scaffold (Formula I),
- stereochemical limitations (erythro; (+) enantiomer),
- salt identity (including explicit sodium 3R,5S-(+)-erythro-(E) example), and
- functional therapeutic linkage to HMG-CoA inhibition via composition and method claims.
- The patent landscape around this subject matter typically clusters around (a) the same active scaffold across stereoisomers, (b) salt selection, and (c) downstream formulation and method-of-use patents. Without the patent’s full specification, dependent claim text beyond the eight claims you provided, file history, and citation data, a complete “all-patents” landscape map cannot be generated from the input alone.
United States Patent 5,177,080 Scope and Claims Analysis: substituted pyridyl dihydroxy heptenoic acids for HMG‑CoA inhibition
What is US 5,177,080 claiming and how broad is the chemical scope?
Core claim strategy: Claim 1 is the broadest independent claim you provided, defined by a structural genus (“substituted pyridyl-dihydroxy-heptenoic acid of the formula (I) or a pharmaceutically acceptable salt thereof”). Claims 2–6 narrow stereochemistry and salt species; claims 8–9 add composition and method-of-treatment coverage tied to HMG‑CoA inhibition.
Claim-by-claim scope (as provided)
| Claim |
Scope type |
Key limitations in plain terms |
Practical enforceability signal |
| 1 |
Chemical genus |
Substituted pyridyl-dihydroxy-heptenoic acid of Formula I (or pharmaceutically acceptable salt) |
Broadest. Covers any compound within Formula I including many substituent permutations, subject to the formula’s variable definitions (not provided in your extract). |
| 2 |
Chemical subgenus |
Claim 1 + erythro configuration |
Narrows to a specific diastereomer family. |
| 3 |
Chemical subgenus |
Claim 1 + (+) enantiomers |
Narrows to absolute configuration (one enantiomer class). |
| 4 |
Chemical subgenus |
Claim 1 + (+) enantiomers + erythro |
Tightest stereochemical class among the simple stereoclaims. |
| 5 |
Salt genus |
Specific counterions: sodium, potassium, magnesium, ammonium |
Targets salt forms even where the free acid is the same. |
| 6 |
Specific species |
Explicit sodium 3R,5S-(+)-erythro-(E)-7-[4-(4-fluorophenyl)-2,6-diisopropyl-5-methoxymethyl-pyridin-3-yl]-3,5-dihydroxy-hept-6-enoate |
A hard “anchor” example. This species can support narrower but very enforceable positioning in litigation. |
| 7 |
Chemical genus/species class (amide derivatives) |
Diastereomeric amides with R2 = C1–C4 alkyl (optionally hydroxyl-substituted) and R3 = H, C1–C4 alkyl, halogen, or C1–C4 alkoxy |
Depends on the missing Formula in claim 7. Without the structure definition, coverage is best treated as an additional derivative family within the same core. |
| 8 |
Composition for functional inhibition |
Composition containing a compound/salt of claim 1 + pharmaceutically acceptable diluent |
Covers formulation vehicles broadly, limited by “diluent” and by inclusion of the claimed compound. |
| 9 |
Method of use |
Method administering an amount effective to inhibit HMG‑CoA in a patient |
Covers clinical use of the claimed compound for this functional outcome; “in a patient in need thereof” is typical treatment claim language. |
Bottom line: The patent’s chemical footprint is Formula I genus plus stereochemical and salt layers, with additional derivative coverage (amide family). The therapeutic part is functional HMG‑CoA inhibition (composition + method), which is often broad in practice because it does not require a specific dosage form, but it does depend on proving the compound’s HMG‑CoA inhibitory capability and that administration is for that purpose.
How do the erythro and (+) enantiomer limitations affect claim breadth?
Erythro restriction (claims 2 and 4)
- Restricts diastereomeric configuration at the relevant stereocenters captured by “erythro.”
- This can reduce design-around risk relative to a racemate claim. If a generic developer can credibly switch to the non-erythro diastereomer family and still meet clinical requirements, that may avoid claims 2 and 4 but not necessarily claim 1 if claim 1 is truly a genus that includes both erythro and non-erythro variants (the extract says claim 1 is broad; claim 2 narrows).
Absolute configuration restriction to (+) enantiomers (claims 3 and 4)
- Narrows to one enantiomer sign.
- If the therapeutic product uses an enantiopure (+) form, this strengthens enforceability. If products are racemic or enantiomerically different, claim 3 and 4 may become harder to assert.
Interplay with claim 6
- Claim 6 is a fully specified salt plus absolute stereochemistry plus named side-chain substituents.
- In practice, species claims often become the litigation focal points because they do not require the court to navigate variable substituent boundaries in the genus.
What patents protect sodium, potassium, magnesium, ammonium salts and specific salt species?
Claim 5 expressly covers salts with Na, K, Mg, and NH4. Claim 6 covers a particular sodium salt with a defined absolute configuration and stereochemistry.
Enforceable salt surface
- If an infringer uses a non-listed salt (eg, calcium) or a different cation, claim 5 may not apply, but claim 1 may still capture the compound “or pharmaceutically acceptable salt” depending on whether “pharmaceutically acceptable salt” is broadly construed to include other cations. The extract suggests claim 1 allows “pharmaceutically acceptable salt,” while claim 5 narrows to enumerated cations.
Design-around signal
- If the marketed form is a different salt not covered by claim 5, claim 1’s “pharmaceutically acceptable salt” language becomes the critical question for infringement. Your extract indicates that claim 1 includes salts, but the exact scope of “pharmaceutically acceptable” is determined by the specification and prosecution record.
What is the role of amide claims (claim 7) in the patent’s coverage?
Claim 7 introduces diastereomeric amides with:
- R2: C1–C4 alkyl, optionally substituted by hydroxyl
- R3: hydrogen, C1–C4 alkyl, halogen, or C1–C4 alkoxy
This claim likely extends protection beyond the acid form into derivative chemistry that may still preserve the “HMG‑CoA inhibition” functional linkage through a shared core.
Practical impact
- If downstream development made prodrugs or amide derivatives (or alternative metabolic precursors), claim 7 can catch those analogs even if the free acid is modified.
- Amide coverage can also be relevant to “salt of active metabolite” strategies, because derivative chemistry is often used to tune solubility and absorption.
What is claimed for compositions and methods of inhibiting HMG‑CoA (claims 8 and 9)?
Composition claim 8
- Requires: a compound or salt according to claim 1 + a pharmaceutically acceptable diluent.
- Does not limit formulation type (tablets, capsules, injectables, etc.) on the face of the provided claim text.
- The breadth will be constrained by whether the product includes the claimed compound itself (not merely a related HMG‑CoA inhibitor).
Method claim 9
- Requires administration of an amount effective to inhibit HMG‑CoA in a patient in need thereof.
- Enforceability hinges on:
- the administered compound being within claim 1’s Formula I,
- and proving that the administered course is for HMG‑CoA inhibition (usually established by mechanism-of-action evidence used in labeling and scientific materials).
Commercial relevance
- Method claims can be leveraged in litigation even when formulation claims are avoided by changing dosage form, so long as the same active compound is used and prescribed/used for the covered function.
Does US 5,177,080 cover a specific drug candidate or an entire chemical program?
The extract is consistent with a patent that underpins a specific chemical class with:
- genus coverage (claim 1),
- stereochemical narrowing (claims 2–4),
- salt coverage (claims 5–6),
- derivative coverage (claim 7),
- and functional therapeutic claims (claims 8–9).
That pattern usually maps to an originator chemical program where the early foundational patent covers core molecules and the most commercially relevant stereoisomer/salt.
What is missing for a complete “which marketed product” mapping
- The patent title, specification examples, and the identity of the exact therapeutic lead compound used in development (the extract does not name the drug).
- Without the specification and example section, it is not possible to tie claim 6’s sodium salt to a specific commercial product name and confirm which stereoisomer/salt is used in marketed therapy.
How do dependent claims create design-around paths for generics or new salts?
Primary design-around axes
- Stereochemistry: switch to a non-(+) enantiomer and/or non-erythro diastereomer family to avoid claims 3 and 4.
- Salt selection: use a cation outside claim 5’s list, though claim 1’s “pharmaceutically acceptable salt” can still capture other salts.
- Derivative substitution: avoid the amide class (claim 7) if focusing on acid-only products.
- Mechanism/indication: method claim 9 is keyed to HMG‑CoA inhibition; changing the therapeutic approach is harder if the compound’s mechanism inherently inhibits HMG‑CoA.
Practical litigation posture
- Litigation usually tests infringement against:
- claim 1 (genus) and claim 6 (species),
- and, where relevant, claim 3/4 and claim 5 for stereochemistry and salt.
How strong is the patent estate for competitive compounds in this HMG‑CoA inhibitor scaffold?
Strength signals from the provided claims
- Multiple claim layers (genus + stereochemistry + salts + species example + composition + method) increase the odds that at least one claim reads onto an infringing product.
- Claim 6 is a fully specified anchor species with concrete structural and salt identity, which often supports clearer infringement theories.
Strength limitations that can reduce scope
- The actual breadth depends on what “substituted” means inside Formula I. The extract does not include the variable definitions or substituent limits.
- Method claim enforcement depends on use and prescriber/patient behavior, and on evidence that the accused product inhibits HMG‑CoA at relevant concentrations.
What is the likely patent expiration profile for US 5,177,080 and how does exclusivity typically end?
- This section cannot be completed from your input because it requires the patent’s filing date, priority date(s), and patent term adjustment/changes, and the patent’s issuance and maintenance status.
- A credible expiration timetable is not derivable from the claim text alone.
Are there Paragraph IV or biosimilar risks relevant to this patent?
- Biosimilar risk is not applicable because this is a small-molecule chemical patent (claims are for substituted acids/salts).
- Paragraph IV risk depends on whether an FDA-approved generic could be approved before patent expiration and whether the Orange Book lists this specific patent against the NDA/ANDA. Those linkage facts are not included in your input.
Which other patents usually coexist around a core chemical Formula I like this?
From the claim structure and typical prosecution strategy, the surrounding ecosystem usually includes:
- follow-on patents on:
- specific polymorphs/solid forms,
- process/manufacturing methods,
- additional stereoisomers or specific salts,
- formulation technologies (controlled release, improved bioavailability),
- and expanded method-of-use/combination regimens.
- chemical patents on close analogs (related substituent sets) that preserve functional overlap with HMG‑CoA inhibition.
This is a pattern-based statement; the specific patent numbers and families cannot be enumerated without the patent bibliographic data and citation set.
Key Takeaways
- US 5,177,080 covers a substituted pyridyl dihydroxy heptenoic acid scaffold (Formula I) and pharmaceutically acceptable salts, with enforceable narrowing through erythro configuration and (+) enantiomer limitations.
- The patent includes:
- salt coverage (Na, K, Mg, NH4) and a fully specified sodium species as claim 6,
- amide derivatives as claim 7 with defined R2/R3 ranges,
- composition and method-of-use claims tied to HMG‑CoA inhibition.
- Enforcing and designing around the estate turns primarily on:
- matching the stereochemistry and salt/cation,
- and on whether the accused compound falls within Formula I’s substituent boundaries (not provided in the extract).
- A complete competitive landscape with specific competing patents, litigation events, Orange Book status, and generic entry timelines cannot be produced from claim text alone.
FAQs
-
What stereochemical elements in US 5,177,080 claims matter most for infringement?
The erythro configuration and (+) absolute enantiomer limitations in claims 2–4 are the main stereochemical constraints.
-
Do the claims require a particular formulation type for infringement?
Claim 8 requires a compound/salt plus a pharmaceutically acceptable diluent, but the extract does not limit dosage form.
-
Can a different salt avoid claim 5 of US 5,177,080?
Claim 5 enumerates Na/K/Mg/NH4 salts, but claim 1 also covers “pharmaceutically acceptable salts,” so salt changes may or may not avoid coverage depending on how claim 1 is construed.
-
Does claim 9 cover any HMG‑CoA inhibition, or only a specific indication?
Claim 9 is framed as administration to inhibit HMG‑CoA in a patient in need thereof, so it keys to the HMG‑CoA inhibition function, not an extract-provided specific disease label.
-
Is claim 7 relevant if the marketed product uses only the free acid (not amides)?
Claim 7 targets diastereomeric amides; if the product does not contain or rely on the amide structures within claim 7, that claim may not be implicated.
References
- United States Patent 5,177,080. (Claim set provided in prompt).
More… ↓
⤷ Start Trial
|
